Evolving landscape of targeted treatment options for HER2-positive gastric/gastroesophageal adenocarcinomas

By sjmartinez • August 3, 2023

Epistola R, Chao J, Lee J. Evolving landscape of targeted treatment options for HER2-positive gastric/gastroesophageal adenocarcinomas. Clin Adv Hematol Oncol. 2023 Jun;21(6):312-320. PMID: 37530637.

Tags: Fellow, Harbor UCLA, Hematology/Oncology, Publications

Related Posts

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design

Plutzky J, Taub PR, Bhatt DL, Al Dhaybi O, Aroda VR, Basile JN, Bloch MJ, Budoff M, Busch RS, Buse JB, Cheung D, Christofides EA,[...]

Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation

Oshima A, Serruys PW, Garg S, McEvoy JW, Wood DA, Doenst T, Taggart DP, Puskas JD, Shajahan A, Sharif F, Miyashita K, Tobe A, Tsai[...]

Microbiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight

Kim KJ, Zhong H, Tai D, Shah P, Park D, Goes V, Li J, Jung C, Kim L, Guzman S, Brar G, Castillo D. Microbiome[...]